Why MaxCyte, Inc.’s (MXCT) Stock Is Up 5.13%
As of Tuesday, July 21, MaxCyte, Inc.’s MXCT share price has surged by 5.13%, which has investors questioning if this is right time to sell.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. The company has strategic partnership with VectorBuilder focused on co-developing a new gene delivery solution. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
Commentary & Analysis
Why MaxCyte, Inc.’s (MXCT) Stock Is Down 6.67%
As of Friday, July 17, MaxCyte, Inc.’s MXCT share price has dipped by 6.67%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why MaxCyte, Inc.’s (MXCT) Stock Is Down 5.99%
As of Thursday, July 16, MaxCyte, Inc.’s MXCT share price has dipped by 5.99%, which has investors questioning if this is right time to buy.Jenna Brashear
Why MaxCyte, Inc.’s (MXCT) Stock Is Up 6.02%
As of Monday, July 13, MaxCyte, Inc.’s MXCT share price has surged by 6.02%, which has investors questioning if this is right time to sell.Jenna Brashear
Why MaxCyte, Inc.’s (MXCT) Stock Is Up 7.41%
As of Monday, July 06, MaxCyte, Inc.’s MXCT share price has surged by 7.41%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | MXCT | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $113.0 | $1,774.7 | 23% |
|
| Shares Out (Mil) | 106.9 | 94.8 | 64% |
|
| Institutional Ownership | 98.1% | 90.1% | 77% |
|
| Float (Mil) | 97.6 | 69.9 | 61% |
|
| Beta | 1.57 | 1.20 | 84% |
|
| Avg Daily Volume (000s) | 808 | 838 | 67% |
|
| Price Change (52-week) |
(50.2%) | 81.0% | 15% |
|
| Growth | MXCT | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 4.7% | 7.8% | 35% |
|
| Net Income (5yr) | (30.5%) | (13.7%) | 13% |
|
| EPS (5yr) | (19.8%) | 0.7% | 13 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (27.7%) | (15.0%) | 22% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 4 | 4 | |
| Current EPS | ($0.093) | ($0.276) | ($0.234) | |
| Month Ago EPS | ($0.093) | ($0.275) | ($0.249) | |
| # Rev Up | 0 | 1 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.095) | ($0.300) | ($0.267) | |
| Year/Year Chg | 111.4% | (34.1%) | (43.7%) | |
| Financials | MXCT | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $32 | $763 | 16% |
|
| Net Income (TTM) (Mil) | ($39) | ($14) | 18% |
|
| EPS (TTM) | ($0.367) | ($0.200) | 30% |
|
| Operating Cash Flow (TTM) (Mil) | ($28) | $53 | 12% |
|
| Net Cash Flow (TTM) (Mil) | ($9) | ($5) | 31% |
|
| Long-Term Debt (Q1) (Mil) | $16 | $270 | 31% |
|
| Enterprise Value (Q1) (Mil) | $27 | $2,430 | 12% |
|
| Valuation | MXCT | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.67 | 3.00 | 13% |
|
| P/E | na | 43.5 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 5.3 | na |
|
| Ratios | MXCT | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 80.5% | 47.6% | 89% |
|
| Net Margin | (121.2%) | (2.9%) | 7% |
|
| ROA | (18.4%) | (3.2%) | 21% |
|
| ROE | (21.3%) | (4.5%) | 23% |
|
| Liabilities to Assets | 13.7% | 43.0% | 8% |
|
| F-Score | 1 | 5 | 1% |
|
MaxCyte, Inc. did not pass any screens on 7/30/2026.
